EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Receptor Status after Neoadjuvant Therapy of Breast Cancer: Significance and Implications

Abeer M Shaaban, Elena Provenzano

Pathobiology · 2022 · 89 (5) · 297-308

DOI: 10.1159/000521880 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Pathobiology, online erschienen am 30.05.2022. Verfasst von Abeer M Shaaban und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cellular Pathology, Queen Elizabeth Hospital Birmingham and Cancer and Genomic Sciences, University of Birmingham, Birmingham, UK. Hauptthemen laut MEDLINE: Breast Neoplasms, Neoadjuvant Therapy. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 14 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Neoadjuvant chemotherapy (NACT) is now established in routine management of early breast cancer. Alterations in oestrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) following NACT are reported, with wide variation in results across series. In larger series, changes in ER status are identified in 5–23%, whilst changes in PR status are more frequent (14.5–67%). HER2 status changes less frequently with loss being more common than gain, and higher rates of change with immunohistochemistry are observed compared to in situ hybridization and following HER2-targeted therapy compared with chemotherapy alone. Triple negative is the most stable molecular subtype with combined ER, and HER2-positive cancers show the highest rate of change. Neoadjuvant endocrine therapy is used less commonly than NACT, and whilst loss of ER is rare, changes in PR status can occur in up to 40% of cases. There is relatively little published data on the impact of change in receptor status on survival outcomes. In patients whose tumours become ER or HER2 positive post-NACT, endocrine or anti-HER2 therapy can be initiated, although evidence from clinical trials is lacking. Most guidelines do not currently recommend routine retesting; however it should be considered in some circumstances.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsNeoadjuvant TherapyBiomarkers, TumorFemaleHumansImmunohistochemistryErb-b2 Receptor Tyrosine KinasesReceptors, EstrogenReceptors, Progesterone

Stichwörter der Autor:innen

Breast cancerNeoadjuvant chemotherapyNeoadjuvant endocrine therapyOestrogen receptor

Substanzen

Biomarkers, TumorErb-b2 Receptor Tyrosine KinasesReceptors, EstrogenReceptors, Progesterone

Autor:innen und Institutionen

  • Department of Cellular Pathology, Queen Elizabeth Hospital Birmingham and Cancer and Genomic Sciences, University of Birmingham, Birmingham, UK.
  • Department of Pathology, Cambridge Breast Unit, and NIHR Cambridge Biomedical Research Centre, Cambridge University Hospitals NHS Trust, Cambridge, UK.

Zitieren

APA

Shaaban, A. M., & Provenzano, E. (2022). Receptor Status after Neoadjuvant Therapy of Breast Cancer: Significance and Implications. Pathobiology, 89(5), 297-308. https://doi.org/10.1159/000521880

Vancouver

Shaaban AM, Provenzano E. Receptor Status after Neoadjuvant Therapy of Breast Cancer: Significance and Implications. Pathobiology. 2022;89(5):297-308. doi:10.1159/000521880

BibTeX
@article{Shaaban2022,
  author = {Shaaban, Abeer M and Provenzano, Elena},
  title = {Receptor Status after Neoadjuvant Therapy of Breast Cancer: Significance and Implications},
  journal = {Pathobiology},
  year = {2022},
  volume = {89},
  number = {5},
  pages = {297--308},
  doi = {10.1159/000521880}
}
Kostenlos starten →